Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872002 | 0.97 | IDO1 (0.50) | IDO1TAAR1LOXL2HRH3HTR2A | |
| SCHEMBL11437281 | 0.87 | IDO1 (0.43) | IDO1TAAR1LOXL2HRH3HTR2A | |
| SCHEMBL18494541 | 0.84 | IDO1 (0.41) | IDO1TAAR1LOXL2HTR2AABAT | |
| SCHEMBL2039301 | 0.84 | LOXL2 (0.42) | IDO1TAAR1LOXL2 | |
| SCHEMBL29897365 | 0.84 | PNMT (0.46) | IDO1TAAR1LOXL2PNMT | |
| SCHEMBL24264540 | 0.84 | IDO1 (0.46) | IDO1TAAR1AGXTABATENPP2 | |
| SCHEMBL16635217 | 0.84 | IDO1 (0.41) | IDO1TAAR1HTR2ATACR1 | |
| SCHEMBL1363469 | 0.84 | PNMT (0.46) | IDO1TAAR1LOXL2PNMT | |
| SCHEMBL1363875 | 0.84 | TACR1 (0.44) | IDO1TAAR1LOXL2HTR2ATACR1 | |
| SCHEMBL27824736 | 0.84 | IDO1 (0.41) | IDO1TAAR1HTR2AABATENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12428397-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4149917-B1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-08-22 | — | — | US | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4353720-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2024-04-17 | — | — | EP | disclosed |
| CN-117396471-A | Novel piperidine derivatives and pharmaceutical compositions for inhibiting autotaxin comprising the same | 株式会社次代生物科学 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023101326-A1 | NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF | 주식회사 넥스트젠바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| US-20230167085-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | disclosed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | disclosed |
| CN-1840527-A | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-10-04 | — | — | CN | disclosed |
| US-6337368-B1 | WATER INSOLUBLE CARRIERS WITH P-NITROBENZOIC ACID, AROMATIC AMINES, AMIDES, SULFONAMIDES AND HYDRAZIDES | KANEKA CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-1008383-A1 | LIPOPROTEIN ADSORBENT AND LIPOPROTEIN ADSORBER MADE WITH THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | IDO1 315/4885TAAR1 244/4885LOXL2 3963/4885 |
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | ENPP2, UACA, ITCH | IDO1 588/4885TAAR1 2013/4885LOXL2 2033/4885 |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | IDO1 325/4885TAAR1 1954/4885LOXL2 2058/4885 |
| US-12428397-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | IDO1 3472/4885TAAR1 4676/4885LOXL2 442/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | IDO1 2441/4885TAAR1 2089/4885LOXL2 4618/4885 |
| US-20230167085-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | IDO1 3472/4885TAAR1 4676/4885LOXL2 442/4885 |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | ENPP2, UACA, ACAT2 | IDO1 534/4885TAAR1 2073/4885LOXL2 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.